Brokerages Set Aquestive Therapeutics Inc (AQST) Price Target at $22.35

Aquestive Therapeutics Inc (NASDAQ:AQST) has received an average rating of “Buy” from the six research firms that are currently covering the stock, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy rating. The average twelve-month price objective among analysts that have covered the stock in the last year is $22.35.

A number of research firms recently weighed in on AQST. BMO Capital Markets dropped their price objective on shares of Aquestive Therapeutics from $24.00 to $21.00 and set an “outperform” rating on the stock in a report on Friday, March 15th. Zacks Investment Research upgraded shares of Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, January 3rd. Lake Street Capital restated a “buy” rating on shares of Aquestive Therapeutics in a research report on Wednesday, February 20th. Finally, Wedbush set a $30.00 price objective on shares of Aquestive Therapeutics and gave the company a “buy” rating in a research note on Friday, March 22nd.

Shares of AQST stock traded up $0.05 on Friday, hitting $6.29. The stock had a trading volume of 82,826 shares, compared to its average volume of 109,027. The company has a market capitalization of $157.09 million and a PE ratio of -2.25. The company has a current ratio of 2.25, a quick ratio of 2.09 and a debt-to-equity ratio of 4.23. Aquestive Therapeutics has a 52-week low of $5.60 and a 52-week high of $20.70.

Aquestive Therapeutics (NASDAQ:AQST) last posted its quarterly earnings results on Thursday, March 14th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.91) by $0.35. The company had revenue of $16.82 million during the quarter, compared to analyst estimates of $17.05 million. Equities research analysts predict that Aquestive Therapeutics will post -1.91 EPS for the current year.

Institutional investors and hedge funds have recently bought and sold shares of the business. New York State Common Retirement Fund bought a new position in shares of Aquestive Therapeutics during the fourth quarter valued at $28,000. Bank of New York Mellon Corp bought a new position in shares of Aquestive Therapeutics in the fourth quarter valued at about $108,000. Millennium Management LLC acquired a new stake in Aquestive Therapeutics in the fourth quarter worth about $145,000. Squarepoint Ops LLC acquired a new stake in Aquestive Therapeutics in the fourth quarter worth about $188,000. Finally, Geode Capital Management LLC increased its position in Aquestive Therapeutics by 77.6% in the fourth quarter. Geode Capital Management LLC now owns 44,208 shares of the company’s stock worth $278,000 after purchasing an additional 19,310 shares during the period. Hedge funds and other institutional investors own 66.01% of the company’s stock.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc, a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery in the United States and internationally.

Further Reading: Growth Stocks

Analyst Recommendations for Aquestive Therapeutics (NASDAQ:AQST)

Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.